Ketobrex Tablet contains Alpha Ketoanalogue (NA), a specialized pharmaceutical agent primarily used as a dietary supplement in the management of chronic kidney disease (CKD). It serves as a nitrogen-free analogue of essential amino acids, facilitating protein synthesis while minimizing nitrogenous waste production, thereby reducing the metabolic burden on compromised renal function. Ketobrex is indicated for patients with moderate to severe renal insufficiency who require protein-restricted diets to delay the progression of renal failure and mitigate uremic symptoms. By providing ketoanalogues, the tablet supports the maintenance of nutritional status without exacerbating azotemia. The mechanism involves transamination of ketoanalogues to essential amino acids in peripheral tissues, promoting anabolism and reducing catabolism. Ketobrex should be administered under medical supervision alongside dietary protein restriction and other standard CKD management strategies. Dosage adjustments are individualized based on renal function, nutritional status, and clinical response. Adverse effects are generally minimal but may include gastrointestinal discomfort or allergic reactions. It is contraindicated in patients with hypersensitivity to any component or in those with acute renal failure. Regular monitoring of renal parameters and nutritional markers is recommended during therapy to optimize outcomes and ensure safety.